incidence and 900,000 to $NZ 4 improvement in reduction in complications. million over five the referral access to years). Over the system etc. traditional medium to longer healers. term there should be a net reduction in hospitalisation costs. Analyse reasons Improves the Per unit price of Potential for Initial analysis for Potentially major for different cost-effectiveness key NCD drugs are major cost price differences savings to MOH prices charged for of essential drugs, competitive when savings. is easily feasible. drug budget. imported and reduces costs. compared to Feasibility of Possible essential NCD others in the reducing costs resistance from drugs such as Pacific and would depend drug suppliers. simvastatin. globally. upon circumstances. Avoid high cost / Reallocates scarce Correctly measure Potential for Technically Opposition from low impact resources to areas the full economic major savings feasible but those who believe interventions of greater impact cost per patient of with little change difficult politically. Government must (including possibly and financial dialysis, and in overall health ‘do everything’ for dialysis) and sustainability. health outcomes, results. a patient (even if ‘futile care’. as well as the cost Variable according it is unaffordable and outcomes of to needs of the or the resources ‘end of life futile population group. could be used to care’. save many more people in alternative uses).
Analyse reasons for different prices charged for imported essential NCD drugs such as simvastatin. Avoid high cost / low impact interventions (including possibly dialysis) and ‘futile care’. Improves the cost-effectiveness of essential drugs, and reduces costs. Reallocates scarce resources to areas of greater impact and financial sustainability. incidence and complications. Per unit price of key NCD drugs are competitive when compared to others in the Pacific and globally. Correctly measure the full economic cost per patient of dialysis, and health outcomes, as well as the cost and outcomes of ‘end of life futile care’. 900,000 to $NZ 4 million over five years). Over the medium to longer term there should be a net reduction in hospitalisation costs. Potential for major cost savings. Potential for major savings with little change in overall health results. Variable according to needs of the population group. improvement in the referral system etc. Initial analysis for price differences is easily feasible. Feasibility of reducing costs would depend upon circumstances. Technically feasible but difficult politically. reduction in access to traditional healers. Potentially major savings to MOH drug budget. Possible resistance from drug suppliers. Opposition from those who believe Government must ‘do everything’ for a patient (even if it is unaffordable or the resources could be used to save many more people in alternative uses).
893050WP0P13040PUBLIC00NCD0Roadmap.docx